Vyome Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HIND research report →
Range $3.5 – $3.5
Price Chart
About the company
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
- CEO
- Venkateswarlu Nelabhotla
- IPO
- 2016
- Employees
- 18
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on HIND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.42M
- P/E
- -2.48
- Fwd P/E
- 1.06
- PEG
- -0.01
- P/S
- 69.22
- P/B
- 1.99
- EV/EBITDA
- -1.03
- Div Yield
- 0.00%
- Gross Margin
- 46.95%
- Op Margin
- -2853.60%
- Net Margin
- -2455.56%
- ROE
- -73.13%
- ROIC
- -63.33%
Latest fiscal year · YoY change
- Revenue
- $319.71K-96.0%
- Gross Profit
- $206.79K-95.9%
- Op Income
- $-2,747,037
- Net Income
- $-10,262,007-43.9%
- EPS
- $-4.75+98.6%
- OCF Growth
- +15.3%
- FCF Growth
- +15.3%
- 52W High
- $5.88
- 52W Low
- $1.20
- 50D MA
- $1.84
- 200D MA
- $2.17
- Beta
- 1.51
- RSI (14)
- 19
- Avg Volume
- 13.44K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ReShape posted modest Q3 revenue growth, improved margins and sharply lower costs, while positioning the company around the Vyome merger and asset sale to maximize shareholder value.· November 14, 2024
- Q3 revenue rose 6.4% year over year and 16.6% sequentially, marking the third straight quarter of revenue growth.
- Gross margin improved to 62.8% in the quarter, helped by lower overhead and payroll costs.
- Operating expenses were reduced by over 40% in the first nine months of 2024 versus last year.
- Management completed the limited launch of Lap-Band 2.0 FLEX, received Health Canada approval, and said initial surgeon feedback was very positive.
- The company is focused on closing the Vyome merger and Biorad asset sale, which management says could maximize shareholder value.
Revenue was $2.3 million in Q3 2024, up 6% year over year and up 17% sequentially; nine-month revenue was $6.2 million, down 7% year over year. Gross profit was $1.4 million in Q3, slightly above $1.3 million a year ago, with gross margin at 63% versus 60% last year; nine-month gross profit was $3.7 million, unchanged year over year, with gross margin at 60% versus 55%. Non-GAAP adjusted EBITDA was $1.6 million in Q3 versus a loss of $2.9 million last year; nine-month adjusted EBITDA loss was $5.6 million versus $12 million last year. Management said operating costs were down 41% for the first nine months of 2024, ending the quarter with $1.3 million of net working capital and $800,000 of cash and restricted cash. No formal quarterly or full-year revenue guidance was given; instead, management emphasized continued commercialization of Lap-Band 2.0 FLEX, Health Canada approval, and completion of the Vyome merger and Biorad asset purchase.
Paul Hickey framed the quarter as evidence that ReShape’s business is stabilizing despite GLP-1 pressure, citing the third straight quarter of revenue growth and early positive feedback on the Lap-Band 2.0 FLEX launch. He was upbeat about the market opportunity for minimally invasive obesity treatments as awareness of obesity care grows, while repeatedly linking shareholder value to the Vyome merger and the Biorad asset sale. His tone was notably optimistic about the transaction, saying the board unanimously recommended it and that the combined deals should maximize value.
Tom Stankovich focused on the cost actions and margin improvement, saying overall operating costs were down 41% in the first nine months of 2024 versus the prior year. He walked through the numbers: Q3 revenue of $2.3 million, gross profit of $1.4 million, gross margin of 63%, sales and marketing down 60% to $700,000, G&A down 30% for the nine-month period, and R&D down 26% in Q3 to $400,000. He also said the company ended the quarter with $1.3 million of net working capital and $800,000 of cash and restricted cash, emphasizing that lower overhead and payroll drove the higher gross margin.
The main analyst question focused on Vyome’s drug pipeline, including the 1953 gel, malignant fungating wounds, and whether the investor presentation would outline which programs move forward, including 1908 and the uveitis indication. Krishna Gupta said the detailed science would be covered in the upcoming investor deck, but confirmed the presentation would outline the three molecules and the near-term catalysts the company plans to pursue. Another question asked whether GLP-1 adoption might eventually help the Lap-Band market rebound; Paul Hickey said he believes there is opportunity over time, citing people who taper off GLP-1s or seek the least invasive option, while noting the obesity market remains underserved.
The quarter showed sequential and year-over-year revenue growth, better gross margins, and a much smaller adjusted EBITDA loss, suggesting the cost reset is working. Management also pointed to positive early reactions to Lap-Band 2.0 FLEX, Health Canada approval, and the possibility that the Vyome merger plus Biorad asset sale could create a more valuable combined company.
Revenue is still small and the nine-month comparison remains down year over year, with management explicitly blaming GLP-1 weight-loss drugs for pressure on the business. Cash and restricted cash were only $800,000 at quarter-end, and much of the investor focus has shifted from the core obesity business to the pending merger and asset transactions, which still depend on approvals and execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 28.8%
- Shares Outstanding
- 7.02M
- Float Shares
- 2.02M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Susquehanna International Group, Llp | 26.55K | ▲ 16.50K |
| Geode Capital Management, LLC | 25.58K | ▼ 213 |
| Vanguard Capital Management LLC | 14.93K | ▲ 5.46K |
| Focus Partners Wealth | 14.64K | 0 |
| Hrt Financial LP | 13.83K | ▼ 6.48K |
| Vanguard Fiduciary Trust Co | 12.20K | 0 |
| Vanguard Group Inc | 12.20K | ▲ 12.20K |
| Royal Bank Of Canada | 5.86K | 0 |
| Ubs Group AG | 3.09K | ▼ 8.82K |
| Tower Research Capital LLC (Trc) | 2.52K | ▲ 708 |
| Fmr LLC | 1.00K | ▲ 1.00K |
| Caitong International Asset Management Co., Ltd | 3 | 0 |
Held by 5 ETFs
Biggest fund positions in HIND by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Jolly Mohanjit | other | 120,000 |
| Sep 1, 26 | Leonard Jerry | other | 0 |
| Nov 13, 25 | Pomichter Stanley D III | other | 17,833 |
| Aug 15, 25 | Pomichter Stanley D III | other | 0 |
| Aug 15, 25 | Jolly Mohanjit | other | 454,456 |
| Aug 15, 25 | Jolly Mohanjit | other | 0 |
| Nov 13, 25 | Tincoff John M. III | other | 17,833 |
| Nov 13, 25 | Sengupta Shiladitya | other | 624,432 |
| Aug 15, 25 | Sengupta Shiladitya | other | 0 |
| Nov 13, 25 | Nelabhotla Venkateswarlu | other | 615,149 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HIND coverage
Recent articles, reports, and earnings notes.
No research on HIND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HIND report →Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
businesswire.com · Nov 16
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
businesswire.com · Oct 26
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
businesswire.com · Oct 5
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
businesswire.com · Sep 14
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
businesswire.com · Aug 25
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
businesswire.com · Jul 1
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
gurufocus.com · May 28
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
businesswire.com · May 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.